Gene expression profiling in acute myeloid leukaemia (AML)

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 2, 2009, Pages 169-180

  Bacher, Ulrike ^a   Kohlmann, Alexander ^b   Haferlach, Claudia ^b   Haferlach, Torsten ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

acute myeloid leukaemia (AML); class discovery; class prediction; gene expression profiling (GEP); the MILE study

Indexed keywords

CD135 ANTIGEN; MICRORNA; NUCLEOPHOSMIN; ONCOPROTEIN; PROTEIN NRAS; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; FOLLOW UP; GENE DUPLICATION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC HETEROGENEITY; GENOMIC INSTABILITY; HUMAN; KARYOTYPING; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION PROFILING; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICROARRAY ANALYSIS; NUCLEAR PROTEINS;

EID: 68749103440     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.04.003     Document Type: Review

References (62)

1. Marcucci G., Mrozek K., and Bloomfield C.D. Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 12 (2005) 68-75
2. Tallman M.S. New agents for the treatment of acute myeloid leukemia. Best Pract Res Clin Haematol 19 (2006) 311-320
3. Illmer T., and Ehninger G. FLT3 kinase inhibitors in the management of acute myeloid leukemia. Clin Lymphoma Myeloma 8 Suppl. 1 (2007) S24-S34
4. Meijer E., and Cornelissen J.J. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. Semin Oncol 35 (2008) 449-457
5. Dohner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106 (2005) 3740-3746
6. Falini B., Mecucci C., Tiacci E., et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352 (2005) 254-266
7. Falini B., Nicoletti I., Martelli M.F., et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 109 (2007) 874-885
8. Wouters BJ, Lowenberg B, Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009;113:291-8.
9. Golub T.R., Slonim D.K., Tamayo P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286 (1999) 531-537
10. Bullinger L., Dohner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350 (2004) 1605-1616
11. Radmacher M.D., Marcucci G., Ruppert A.S., et al. Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 108 (2006) 1677-1683
12. Raponi M., Lancet J.E., Fan H., et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 111 (2008) 2589-2596
13. Kohlmann A., Schoch C., Dugas M., et al. Pattern robustness of diagnostic gene expression signatures in leukemia. Genes Chromosomes Cancer 42 (2005) 299-307
14. Kornblau SM, Tibes R, Qiu Y, et al. Functional proteomic profiling of AML predicts response and survival. Blood 2009;113:154-64.
15. Suela J., Alvarez S., and Cigudosa J.C. DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 118 (2007) 304-309
16. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 (2008) 1919-1928
17. Kohlmann A., Haschke-Becher E., Wimmer B., et al. Intraplatform reproducibility and technical precision of gene expression profiling in 4 laboratories investigating 160 leukemia samples: the DACH study. Clin Chem 54 (2008) 1705-1715
18. Schoch C., Kohlmann A., Schnittger S., et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 99 (2002) 10008-10013
19. Debernardi S., Lillington D.M., Chaplin T., et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 37 (2003) 149-158
20. Verhaak RG, Wouters BJ, Erpelinck CA, et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 2009;94:131-4.
21. Armstrong S.A., Staunton J.E., Silverman L.B., et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30 (2002) 41-47
22. Kohlmann A., Schoch C., Dugas M., et al. New insights into MLL gene rearranged acute leukemias using gene expression profiling: shared pathways, lineage commitment, and partner genes. Leukemia 19 (2005) 953-964
23. Haferlach T., Kohlmann A., Schnittger S., et al. AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer 43 (2005) 113-127
24. Camos M., Esteve J., Jares P., et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 66 (2006) 6947-6954
25. Murati A, Gervais C, Carbuccia N, et al. Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia 2009;23:85-94.
26. Virtaneva K., Wright F.A., Tanner S.M., et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A 98 (2001) 1124-1129
27. Schoch C., Kohlmann A., Dugas M., et al. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia 19 (2005) 1224-1228
28. Schoch C., Haferlach T., Bursch S., et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 35 (2002) 20-29
29. Schoch C., Kern W., Kohlmann A., et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 43 (2005) 227-238
30. Lindvall C., Furge K., Bjorkholm M., et al. Combined genetic and transcriptional profiling of acute myeloid leukemia with normal and complex karyotypes. Haematologica 89 (2004) 1072-1081
31. Verhaak R.G., Goudswaard C.S., van P.W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106 (2005) 3747-3754
32. Alcalay M., Tiacci E., Bergomas R., et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc + AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 106 (2005) 899-902
33. Wilson C.S., Davidson G.S., Martin S.B., et al. Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108 (2006) 685-696
34. Mullighan C.G., Kennedy A., Zhou X., et al. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 21 (2007) 2000-2009
35. Neben K., Schnittger S., Brors B., et al. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 24 (2005) 1580-1588
36. Whitman S.P., Ruppert A.S., Radmacher M.D., et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111 (2008) 1552-1559
37. Lacayo N.J., Meshinchi S., Kinnunen P., et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104 (2004) 2646-2654
38. Bullinger L., Dohner K., Kranz R., et al. An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 111 (2008) 4490-4495
39. Valk P.J., Verhaak R.G., Beijen M.A., et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350 (2004) 1617-1628
40. Metzeler K.H., Hummel M., Bloomfield C.D., et al. An 86 probe set gene expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112 (2008) 4193-4201
41. Wouters B.J., Jorda M.A., Keeshan K., et al. Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 110 (2007) 3706-3714
42. Marcucci G., Baldus C.D., Ruppert A.S., et al. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 23 (2005) 9234-9242
43. Bullinger L., Rucker F.G., Kurz S., et al. Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 110 (2007) 1291-1300
44. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107 (2006) 3463-3468
45. Bourquin J.P., Subramanian A., Langebrake C., et al. Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A 103 (2006) 3339-3344
46. Andreeff M, Ruvolo V, Gadgil S, et al. HOX expression patterns identify a common signature for favorable AML. Leukemia 2008;22:2041-7.
47. Raghavan M., Smith L.L., Lillington D.M., et al. Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. Blood 112 (2008) 814-821
48. Gupta M., Raghavan M., Gale R.E., et al. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia. Genes Chromosomes Cancer 47 (2008) 729-739
49. Gondek L.P., Tiu R., O'Keefe C.L., et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111 (2008) 1534-1542
50. Suela J., Alvarez S., Cifuentes F., et al. DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups. Leukemia 21 (2007) 1224-1231
51. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 111 (2008) 3183-3189
52. Jongen-Lavrencic M., Sun S.M., Dijkstra M.K., et al. MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111 (2008) 5078-5085
53. Heuser M., Wingen L.U., Steinemann D., et al. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica 90 (2005) 1484-1492
54. Langer C., Radmacher M.D., Ruppert A.S., et al. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood 111 (2008) 5371-5379
55. Steinbach D., Schramm A., Eggert A., et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 12 (2006) 2434-2441
56. Willman C.L. Has gene expression profiling improved diagnosis, classification, and outcome prediction in AML?. Best Pract Res Clin Haematol 21 (2008) 21-28
57. Haferlach T., Kohlmann A., Schnittger S., et al. Global approach to the diagnosis of leukemia using gene expression profiling. Blood 106 (2005) 1189-1198
58. Baldus C.D., and Bullinger L. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. Semin Oncol 35 (2008) 356-364
59. Schlenk R.F., Dohner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358 (2008) 1909-1918
60. Stapnes C., Ryningen A., Hatfield K., et al. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol 31 (2007) 1529-1538
61. Haferlach T. Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. ASH, Hematology AM Soc Hematol Educ Program, 2008;400-11.
62. Kohlmann A., Kipps T.J., Rassenti L.Z., et al. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in Leukemia study prephase. Br J Haematol 142 (2008) 802-807